The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
about
Pharmacogenetic studies update in type 2 diabetes mellitusNew insights in bilirubin metabolism and their clinical implicationsIndividualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Impact of OATP transporters on pharmacokinetics.Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sexPharmacogenetics and personalized treatment of type 2 diabetesHepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Repaglinide: a review of its use in type 2 diabetes mellitus.Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Pharmacogenomics of glinides.Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative ProteomicsRare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response.Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis.PharmGKB very important pharmacogene: SLCO1B1.Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination.The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide.Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers.Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions.Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans
P2860
Q26739350-A5271880-D7D8-4D09-8F58-05223A08FB17Q26863145-01008800-9174-4C25-AAB6-9F745E16315AQ30571118-AA948470-9DA1-4D28-83CA-782987EC3FCDQ30776360-04551101-D4C3-4E35-928C-209202920C57Q33993320-C504E084-721C-40D9-ADB9-2A7C51FF56D8Q34612244-41FF6863-11E7-4E61-9027-5DE62B06D8E3Q37422685-53C5FA0F-C5DD-4891-8655-2ECCCB54349CQ37508445-E5EA721D-2BDF-4C15-867C-089ED80D1D39Q37680968-951269E6-1FC8-46E8-AE1A-C09C6A646F1EQ37977979-A6C2A3FE-1B84-4361-9E96-9AFE8BDC1F3FQ38003174-55C13DE5-77B2-47FC-B959-69837430D00DQ38307994-7BE7BEF1-9504-487E-92A6-445D5B088FE8Q38829596-C56F3420-D304-461D-94AF-B2A059881290Q39833609-C34E0316-56D6-474C-9320-4B3CAAF3C2DCQ41647064-AAD052E7-661E-4851-8EAB-0ACB9F4A34BEQ42726145-91E89409-747D-4D44-9CBC-EBD971D604D9Q43767845-6E74076F-B156-411D-B2E4-FD3A9A88153AQ48068001-BDD29CD4-9183-4B09-B60C-A311F71BF481Q48809049-6E0F435F-983B-4F16-A950-CD79652149D9Q51696345-20FE21CC-7CED-4596-BF91-71EA41C232AEQ54387375-B2A21BDA-F64F-45B5-99EE-538F88605799Q55046512-3C4A9A84-58F1-45E5-AD1A-7CE6A62CC68FQ57825125-4B63B941-991C-4961-8F04-3F1CC027B25C
P2860
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The effect of SLCO1B1 polymorp ...... rsists over a wide dose range.
@en
The effect of SLCO1B1 polymorp ...... rsists over a wide dose range.
@nl
type
label
The effect of SLCO1B1 polymorp ...... rsists over a wide dose range.
@en
The effect of SLCO1B1 polymorp ...... rsists over a wide dose range.
@nl
prefLabel
The effect of SLCO1B1 polymorp ...... rsists over a wide dose range.
@en
The effect of SLCO1B1 polymorp ...... rsists over a wide dose range.
@nl
P2860
P50
P1476
The effect of SLCO1B1 polymorp ...... rsists over a wide dose range.
@en
P2093
Annikka Kalliokoski
P2860
P304
P356
10.1111/J.1365-2125.2008.03287.X
P407
P577
2008-09-23T00:00:00Z